The Kratom Council

Latest / Regulation

Regulation

In August The Industry Sued Because A Reassurance Sat In A Press Release Rather Than In The Order. In October A Number Appeared In The Order.

A polished dark hardwood judge’s gavel with a brass band around its head, hanging unsupported in mid air a few inches above its round wooden sounding block. The block rests on a mahogany bench with a green leather top, warm sunlight falls across it from the left, and the wall behind is deep teal.

This publication reported on September 2 that two lawsuits filed within a week of each other made the same argument from opposite directions. The federal one was the narrower and the stranger. The American Kratom Association was not asking a court to strike down the temporary scheduling order covering mitragynine pseudoindoxyl, MGM-15 and MGM-16. It was asking the court to say what the order did not reach.

The hinge of that case was a document problem rather than a chemistry problem. On the association's account, the Department of Justice had addressed enforcement discretion for incidental trace amounts of mitragynine pseudoindoxyl in a news release, and that language did not appear in the order itself. The suit asked a judge to put the reassurance somewhere it would bind.

On October 14 a threshold for that compound appeared in a notice of intent. On October 9 the association said its litigation was resolved.

What The Suit Actually Asked For

The case is American Kratom Association v. Drug Enforcement Administration and others, filed August 27 in the United States District Court for the District of Columbia and docketed as Case No. 1:26-cv-02997. The named defendants are the agency, its Administrator Terrance C. Cole, and the Department of Justice.

As reported, the relief sought was declaratory and injunctive, and it was specific. The association wanted confirmation that the temporary scheduling order does not reach traditional botanical kratom products merely because modern testing can detect incidental, naturally occurring or naturally formed trace amounts of mitragynine pseudoindoxyl. It stated expressly that it was not seeking protection for intentionally manufactured, concentrated, fortified or enhanced products containing that compound.

That distinction is the whole case. An order written against a compound reaches anything the compound is found in, at any quantity an instrument can measure. A detection limit is not a policy decision, but in an order with no floor it becomes one.

A Threshold Does The Thing The Suit Asked A Judge To Do

The notice of intent published October 14, Federal Register document 2026-20943, names 7-hydroxymitragynine and mitragynine pseudoindoxyl together and proposes to control either substance, or the two combined, above a specified threshold rather than at any detectable quantity.

Read against the complaint, that is the same remedy arriving by a different route. The association asked a court to declare that trace quantities fall outside the order. A threshold written into the instrument accomplishes that without a judge, because below the figure there is nothing to declare.

This publication reported on October 15 that a substance controlled in August without qualification had become the subject of a proposal to control it conditionally, and declined at the time to characterise why. This is the most plausible account of why, and it is worth being exact about its status: it is an inference from sequence and from the association's own description, not something either agency has said.

What The Association Said, And What It Did Not

On October 9 the association issued a statement commending the agency and the department for what it described as targeted scheduling of the two compounds, and welcoming what it called the resolution of its litigation over the unintended consequences of the earlier scheduling action.

Those are its characterisations and this publication does not adopt them. Targeted is an assessment, not a finding. Resolution is a word a party can use about its own case before a court has entered anything, and the search record available here contains no order, no stipulation of dismissal and no docket entry describing how the matter ended.

What the association did not claim, at least in anything reachable here, is that the agency acted because it sued. The sequence is public and the inference is available to anyone, but the association appears to have stopped short of asserting causation, and so does this publication.

The Order Has Still Not Issued, And The Notice Now Names A Date

The temporary scheduling order for 7-hydroxymitragynine has not published. What exists is notice of an intent to issue one.

On the reporting available, the October 14 notice states that the temporary scheduling order will be published in the Federal Register on or after November 13, 2026. That is a correction this publication owes its own readers. Our October 15 article said the documents carried a placeholder rather than a printed date and described November 13 as this publication's own arithmetic. The figure appears to be printed in the notice. The sentence making the claim about what the documents do not contain has been removed from that article.

The August 26 order covering mitragynine pseudoindoxyl is reported to remain in force until it expires, or until the new order publishes and the earlier one is withdrawn, whichever comes first. Until that happens the compound is controlled with no threshold at all, which is the condition the August lawsuit was brought over.

Why This Matters Past The Litigation

The useful finding here is not that an association won something. It is where the dispute was located.

Both the federal suit and the Massachusetts retailers' case this publication reported alongside it argued about instruments rather than about kratom. One said the reassurance was in the wrong document. The other said three statutory findings had not been made. Neither asked a court to weigh the merits of the substance.

An operator reading only headlines would take from the past two months that the federal government is deciding whether these compounds should be controlled. The documents describe something narrower and more procedural: a sequence of arguments about what a given instrument says, where it says it, and whether the thing that was promised appears in the text that binds.

Sourcing, Plainly

Nothing in this article was retrieved. The Federal Register, govinfo, congress.gov, justice.gov and courthousenews are unreachable from this publication's working environment, so neither the notice nor the complaint nor any docket was opened, and the piece carries no quotation marks anywhere for that reason.

The case number, the court, the filing date, the named defendants and the relief sought are consistent across separate accounts and are treated here as established. The association's October 9 statement is reported as its statement. The publication date on or after November 13 comes from descriptions of the notice and is the load-bearing new fact in this article.

Two things are expressly not established. Whether any court entered an order or the parties stipulated to anything, and whether either agency attributes the threshold to the litigation. A Congressional Research Service product on the temporary control of these substances exists and is listed below as a background source that was likewise not opened.

Sources

  1. Reporting on the October 14, 2026 notices of intent and on American Kratom Association v. Drug Enforcement Administration, as it appears in search results. No document, filing or docket was reachable from this publication's working environment and none was opened directly.
  2. Federal Register — Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I, document 2026-20943 (October 14, 2026)
  3. govinfo — Federal Register Vol. 91, No. 197, document 2026-20943 (October 14, 2026)
  4. Federal Register — the withdrawn notice of intent of July 6, 2026, document 2026-13580
  5. Congressional Research Service — Temporary Control of 7-Hydroxymitragynine (7-OH) and Other Kratom-Related Substances Under the Controlled Substances Act, LSB11457
  6. American Kratom Association — statement on the scheduling of 7-OH and mitragynine pseudoindoxyl (October 9, 2026)
  7. Fortune press releases — the same association statement (October 9, 2026)
  8. American Kratom Association — announcement of the federal lawsuit over the enforcement discretion gap (August 2026)
  9. Inside Health Policy — "Kratom Organization Sues DEA Over Scheduling Order"
  10. The Kratom Council — "The Industry Went To Court Twice In A Week" (September 2, 2026)
  11. The Kratom Council — "The July Threshold Was Withdrawn, Not Superseded" (October 15, 2026)
  12. The Kratom Council — "For Fifteen Weeks The Trade Watched One Number" (October 12, 2026)
  13. The Kratom Council — "What The August 26 Scheduling Order Actually Covers, And What It Does Not" (August 30, 2026)

← Back to all coverage

Get new reporting by email